Clinical Trials Logo
  1. Home
  2. AML, Adult
  3. NCT05839392
  4. Details
NCT05839392 Clinical Trial

Novel Approaches to Target MECOM/EVI1 in AML

AML, Adult Clinical Trial

Official title:
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05839392
Other study ID # AML2623
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 13, 2023
Est. completion date December 2026

Study information
Verified date December 2023
Source Gruppo Italiano Malattie EMatologiche dell'Adulto
Contact Paola Fazi
Phone 0670390528
Email p.fazi@gimema.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Description:

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Recruitment information / eligibility
Status Recruiting
Enrollment 24
Est. completion date December 2026
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - AML with MECOM or atypical 3q26 rearrangements. - Age =18. - Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Biological characterization of AML with MECOM or atypical 3q26 rearrangements
Peripheral blood and bone marrow withdrawal

Locations
Country Name City State
Italy Ematologia Piacenza

Sponsors (1)
Lead Sponsor Collaborator
Gruppo Italiano Malattie EMatologiche dell'Adulto

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable To assess the number of regulators or effectors of MECOM/EVI1 At baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Not yet recruiting NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML Phase 1
Terminated NCT04079738 - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Phase 1/Phase 2
Recruiting NCT06052813 - A Study of BN104 in the Treatment of Acute Leukemia Phase 1/Phase 2
Recruiting NCT06027853 - Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia Phase 1
Completed NCT02986620 - Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
Recruiting NCT05601466 - Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia Phase 1
Recruiting NCT06066905 - A Study of Chidamide With AZA in MRD Positive AML After Transplant N/A
Recruiting NCT05909501 - Assessment of Geriatric Evaluations Impact on New AML Guidance
Terminated NCT04614636 - FT538 in Subjects With Advanced Hematologic Malignancies Phase 1
Not yet recruiting NCT06420063 - Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML Phase 1/Phase 2
Withdrawn NCT04128020 - Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Phase 1
Active, not recruiting NCT04749355 - Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS Phase 2
Active, not recruiting NCT04755244 - A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) Phase 1/Phase 2
Completed NCT03194685 - Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Not yet recruiting NCT06377579 - OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Recruiting NCT03884829 - A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Phase 1
Active, not recruiting NCT05177731 - Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML Phase 3
Recruiting NCT05025098 - Precision Therapy Versus Standard Therapy in AML and MDS in Elderly Phase 2
Not yet recruiting NCT06297772 - Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR Phase 3